Granules India Limited
GRANULES · Pharma · NSE
₹645
Current Market Price
Fair Value (DCF)
₹658
Margin of Safety
+2.0%
Updated just now
YieldIQ Score
51/100
Piotroski F-Score
6/9
Economic Moat
Narrow
Confidence
43%
ROE
13.5%
Debt/Equity
0.00
WACC
11.0%
Market Cap
₹0.16 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
17.0%
Return on capital employed
EV / EBITDA
16.9×
Enterprise multiple
Debt / EBITDA
1.7×
Leverage vs earnings
Interest Coverage
11.9×
EBIT covers interest
Current Ratio
1.56×
Short-term liquidity
Asset Turnover
0.73×
Revenue per ₹ of assets
Revenue CAGR (3Y)
—
3-year revenue growth
Revenue CAGR (5Y)
9.4%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹645.35
Bear case
₹393.27
MoS -64.1%
Base case
₹658.13
MoS +1.9%
Bull case
₹890.41
MoS +27.5%
Ratio Trends
GRANULES · last 8 annual periods
ROE
13.5%
ROCE
18.3%
Operating Margin
—
Debt / Equity
0.39×
PE
60.2×
EV / EBITDA
8.6×
Historical Financials
GRANULES · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹3238 Cr | ₹3765 Cr | ₹1196 Cr | ₹1176 Cr | ₹4456 Cr | +8.3% |
| EBITDA | — | ₹728 Cr | ₹907 Cr | ₹826 Cr | ₹946 Cr | +6.8% |
| EBIT | ₹731 Cr | ₹581 Cr | ₹183 Cr | ₹204 Cr | — | -27.3% |
| PAT | ₹549 Cr | ₹413 Cr | ₹120 Cr | ₹130 Cr | ₹502 Cr | -2.3% |
| EPS (diluted) | ₹21.95 | ₹16.60 | ₹4.93 | ₹5.35 | — | -29.7% |
| CFO | ₹432 Cr | ₹332 Cr | ₹739 Cr | ₹439 Cr | ₹867 Cr | +19.0% |
| CapEx | — | — | — | — | ₹-572 Cr | — |
| FCF | — | — | — | — | ₹295 Cr | +0.0% |
| Total Assets | — | ₹4513 Cr | ₹4905 Cr | ₹5521 Cr | ₹6253 Cr | +8.5% |
| Total Debt | — | — | ₹910 Cr | ₹1154 Cr | ₹1455 Cr | +12.4% |
| Shareholders' Equity | — | — | ₹2835 Cr | ₹3226 Cr | ₹3716 Cr | +7.0% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
GRANULES vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| APLLTD APLLTD | — | — | Pending | 11.2% | — |
| COHANCE COHANCE | — | — | Pending | 14.6% | — |
| JUBLPHARMA JUBLPHARMA | — | — | Pending | 13.5% | — |
| NEULANDLAB NEULANDLAB | — | — | Pending | 17.1% | — |
| PPLPHARMA Piramal Pharma Limited | +15.0% | 37 | Fairly valued | 112.2% | — |
Click a ticker to view its fair-value analysis.
Dividend History
29 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹6.75/sh
Last payout
2025-07-31
₹1.50
Peak payout
₹1.50
Trailing yield
0.23%
Amounts parsed from NSE subject lines; percent-of-face-value declarations are not converted and shown as missing.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Granules India Limited (GRANULES.NS) trades at 645.35 vs a model fair value of 658.13, a gap of 2.0%. Piotroski F-score: 6/9. Moat label:...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of GRANULES →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for GRANULES →
Compare
Head-to-head with peers
Compare GRANULES side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse GRANULESNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.